247 related articles for article (PubMed ID: 32488496)
21. EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
Semmlinger A; von Schoenfeldt V; Wolf V; Meuter A; Kolben TM; Kolben T; Zeder-Goess C; Weis F; Gallwas J; Wuerstlein R; Hermelink K; Schmoeckel E; Harbeck N; Mayr D; Mahner S; Jeschke U; Ditsch N
BMC Cancer; 2018 Apr; 18(1):431. PubMed ID: 29661238
[TBL] [Abstract][Full Text] [Related]
22. Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-κB, and AP-1 signaling pathways.
Khoi PN; Xia Y; Lian S; Kim HD; Kim DH; Joo YE; Chay KO; Kim KK; Jung YD
Int J Oncol; 2014 Oct; 45(4):1760-8. PubMed ID: 25069788
[TBL] [Abstract][Full Text] [Related]
23. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
24. Opposing effects of prostaglandin E
Carboneau BA; Allan JA; Townsend SE; Kimple ME; Breyer RM; Gannon M
Mol Metab; 2017 Jun; 6(6):548-559. PubMed ID: 28580285
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
26. Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Smaradhania N; Rahman S; Ardi Syamsu S; Prihantono P
Breast Dis; 2021; 40(S1):S1-S7. PubMed ID: 34057113
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia inducible factor-1 mediates upregulation of urokinase-type plasminogen activator receptor gene transcription during hypoxia in cervical cancer cells.
Nishi H; Sasaki T; Nagamitsu Y; Terauchi F; Nagai T; Nagao T; Isaka K
Oncol Rep; 2016 Feb; 35(2):992-8. PubMed ID: 26718775
[TBL] [Abstract][Full Text] [Related]
28. Actinidia chinensis Planch root extract (acRoots) inhibits hepatocellular carcinoma progression by inhibiting EP3 expression.
Fang T; Hou J; He M; Wang L; Zheng M; Wang X; Xia J
Cell Biol Toxicol; 2016 Dec; 32(6):499-511. PubMed ID: 27475644
[TBL] [Abstract][Full Text] [Related]
29. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
[TBL] [Abstract][Full Text] [Related]
30. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
31. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.
Wang S; Jiang L; Han Y; Chew SH; Ohara Y; Akatsuka S; Weng L; Kawaguchi K; Fukui T; Sekido Y; Yokoi K; Toyokuni S
Oncotarget; 2016 Oct; 7(43):69565-69578. PubMed ID: 27602956
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
33. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
34. Relationship between urokinase plasminogen activator receptor (uPAR) and the invasion of human prenatal hair follicle.
Gao Q; Fu G; Huang G; Lian X; Yu J; Yang T
Arch Dermatol Res; 2010 Aug; 302(6):409-18. PubMed ID: 20012874
[TBL] [Abstract][Full Text] [Related]
35. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
[TBL] [Abstract][Full Text] [Related]
36. N-3 long-chain polyunsaturated fatty acids inhibit smooth muscle cell migration by modulating urokinase plasminogen activator receptor through MEK/ERK-dependent and -independent mechanisms.
Whyte C; Thies F; Peyrol L; Balcerzak D
J Nutr Biochem; 2012 Nov; 23(11):1378-83. PubMed ID: 22221673
[TBL] [Abstract][Full Text] [Related]
37. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.
Jo M; Lester RD; Montel V; Eastman B; Takimoto S; Gonias SL
J Biol Chem; 2009 Aug; 284(34):22825-33. PubMed ID: 19546228
[TBL] [Abstract][Full Text] [Related]
38. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
39. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer.
Saldanha RG; Xu N; Molloy MP; Veal DA; Baker MS
J Proteome Res; 2008 Nov; 7(11):4792-806. PubMed ID: 18808175
[TBL] [Abstract][Full Text] [Related]
40. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
